Luxbright AB (publ) (LXB.ST)
SEK 0.82
(-3.55%)
SEK 0.82
(-3.55%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -25.8 Million SEK | -19.89% |
| 2022 | -21.52 Million SEK | -20.15% |
| 2021 | -17.91 Million SEK | -45.73% |
| 2020 | -12.29 Million SEK | -16.53% |
| 2019 | -10.54 Million SEK | 12.68% |
| 2018 | -12.08 Million SEK | -1.54% |
| 2017 | -11.89 Million SEK | -113.13% |
| 2016 | -5.58 Million SEK | -197.55% |
| 2015 | -1.87 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -4.64 Million SEK | 65.87% |
| 2024 Q2 | -4.64 Million SEK | 0.0% |
| 2023 Q2 | -12.4 Million SEK | -99.77% |
| 2023 Q4 | -13.59 Million SEK | -101.94% |
| 2023 FY | -25.8 Million SEK | -19.89% |
| 2023 Q3 | -6.73 Million SEK | 45.71% |
| 2023 Q1 | -6.2 Million SEK | 42.84% |
| 2022 Q2 | -11.11 Million SEK | -112.26% |
| 2022 Q4 | -10.86 Million SEK | -103.46% |
| 2022 Q3 | -5.33 Million SEK | 51.97% |
| 2022 Q1 | -5.23 Million SEK | 42.46% |
| 2022 FY | -21.52 Million SEK | -20.15% |
| 2021 Q1 | -4.4 Million SEK | 44.77% |
| 2021 Q2 | -9.51 Million SEK | -115.89% |
| 2021 Q3 | -4.55 Million SEK | 52.16% |
| 2021 Q4 | -9.1 Million SEK | -100.0% |
| 2021 FY | -17.91 Million SEK | -45.73% |
| 2020 Q4 | -7.97 Million SEK | -119.9% |
| 2020 Q2 | -5.06 Million SEK | -100.93% |
| 2020 Q3 | -3.62 Million SEK | 28.33% |
| 2020 FY | -12.29 Million SEK | -16.53% |
| 2020 Q1 | -2.51 Million SEK | 60.7% |
| 2019 Q3 | -3.05 Million SEK | 50.12% |
| 2019 FY | -10.54 Million SEK | 12.68% |
| 2019 Q4 | -6.41 Million SEK | -109.65% |
| 2019 Q2 | -6.12 Million SEK | -176.49% |
| 2019 Q1 | -2.21 Million SEK | 0.0% |
| 2018 FY | -12.08 Million SEK | -1.54% |
| 2017 FY | -11.89 Million SEK | -113.13% |
| 2016 FY | -5.58 Million SEK | -197.55% |
| 2015 FY | -1.87 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Acarix AB (publ) | -77.55 Million SEK | 66.727% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 108.584% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 108.584% |
| Arcoma AB | 4.66 Million SEK | 653.743% |
| Bactiguard Holding AB (publ) | -131.93 Million SEK | 80.441% |
| BICO Group AB (publ) | -618.3 Million SEK | 95.827% |
| Boule Diagnostics AB (publ) | 39.27 Million SEK | 165.71% |
| CellaVision AB (publ) | 167.05 Million SEK | 115.447% |
| Clinical Laserthermia Systems AB (publ) | -65.93 Million SEK | 60.863% |
| Chordate Medical Holding AB (publ) | -29.57 Million SEK | 12.739% |
| C-Rad AB (publ) | 44.24 Million SEK | 158.323% |
| Duearity AB (publ) | -25.76 Million SEK | -0.161% |
| Dignitana AB (publ) | -15.02 Million SEK | -71.732% |
| Episurf Medical AB (publ) | -94.8 Million SEK | 72.78% |
| Getinge AB (publ) | 3.81 Billion SEK | 100.677% |
| Scandinavian Real Heart AB (Publ) | -68.44 Million SEK | 62.299% |
| Iconovo AB (publ) | -45.77 Million SEK | 43.63% |
| Integrum AB (publ) | 6.51 Million SEK | 496.239% |
| Mentice AB (publ) | -679 Thousand SEK | -3700.359% |
| OssDsign AB (publ) | -91.95 Million SEK | 71.938% |
| Paxman AB (publ) | 12.61 Million SEK | 304.489% |
| Promimic AB (publ) | -9.11 Million SEK | -183.005% |
| Qlife Holding AB (publ) | -168.69 Million SEK | 84.704% |
| SciBase Holding AB (publ) | -53.93 Million SEK | 52.16% |
| ScandiDos AB (publ) | -13.48 Million SEK | -91.385% |
| Sectra AB (publ) | 518.49 Million SEK | 104.977% |
| Sedana Medical AB (publ) | -65.54 Million SEK | 60.632% |
| Senzime AB (publ) | -133.74 Million SEK | 80.706% |
| SpectraCure AB (publ) | -21.35 Million SEK | -20.858% |
| Stille AB | 44.95 Million SEK | 157.404% |
| Vitrolife AB (publ) | -3.58 Billion SEK | 99.281% |
| Xvivo Perfusion AB (publ) | 38.5 Million SEK | 167.014% |